Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

shankar besta

  • Home
  • Author: shankar besta

Evercore and Houlihan Lokey top M&A financial advisers in technology, media, and telecom sector during Q1 2024

Evercore and Houlihan Lokey were the top mergers and acquisitions (M&A) financial advisers in the technology, media, and telecom (TMT) sector during the first quarter (Q1) of 2024 by value and volume, respectively, according to the latest financial advisers league table by GlobalData, a leading data and analytics company. An analysis of GlobalData’s Deals Database […]
Read more

Skadden, Arps, Slate, Meagher & Flom and Kirkland & Ellis top M&A legal advisers in technology, media, and telecom sector during Q1 2024

Skadden, Arps, Slate, Meagher & Flom and Kirkland & Ellis were the top mergers and acquisitions (M&A) legal advisers in the technology, media, and telecom (TMT) sector during the first quarter (Q1) of 2024 by value and volume, respectively, according to the latest legal advisers league table by GlobalData, a leading data and analytics company. […]
Read more

SherpaPak trial success likely to drive further innovation in organ preservation equipment market, says GlobalData

Paragonix, an organ transplant storage technology company, announced the successful completion of the GUARDIAN-Heart trial in the US. The trial aimed to determine if the SherpaPak Cardiac Transport System technology was superior to existing ice-box transplant storage solutions for donor hearts that are currently on the market. The organ preservation equipment market is growing quickly […]
Read more

Hospitalized incident cases of MRSA to reach 791,000 in 7MM in 2033, forecasts GlobalData

The burden of hospitalized incident cases of methicillin-resistant Staphylococcus aureus (MRSA) is forecast to increase at an annual growth rate (AGR) of 1.08% from around 714,000 cases in 2023 to 791,000 cases in 2033 in the seven major markets (7MM*), according to GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘Methicillin Resistant Staphylococcus […]
Read more

AI sets in motion next wave of disruption in insurance, reveals Technology Foresights by GlobalData

Artificial intelligence (AI) has been instrumental in shaping the insurance industry for the past few years. Insurance providers have integrated AI models with established methodologies from the actuarial sciences to enhance risk analysis and streamline claim processing workflows. Recent progress in AI, supported by Large Language Models (LLMs) and generative AI, marks a new phase […]
Read more

ACC 24: Empagliflozin remains competitive therapy in HF market despite EMPACT-MI trial outcome, says GlobalData

At the American College of Cardiology’s (ACC) 73rd Annual Scientific Session, the results of Eli Lilly and Boehringer Ingelheim’s Phase III EMPACT-MI trial, which examined patients treated with sodium-glucose co-transporter-2 inhibitor (SGLT-2I) empagliflozin (Jardiance) following a heart attack, were reported. However, the treatment with empagliflozin did not impact the study’s primary endpoint of a combination […]
Read more

CaranX Medical’s TAVI success highlights transformative potential of robotic-assisted techniques in cardiovascular medicine, says GlobalData

CaranX Medical, an innovative medical technologies company, announced the successful completion of the world’s first robotic Transcatheter Aortic Valve Implantation (TAVI) procedure. The completion marks a significant milestone in the field of interventional cardiology, showcasing the transformative potential of robotic-assisted techniques in cardiovascular medicine, says GlobalData, a leading data and analytics company. According to GlobalData, […]
Read more

Roche’s PRX-002 shows promise in slowing Parkinson’s disease motor progression, says GlobalData

There are currently no marketed disease-modifying therapies (DMTs) for Parkinson’s disease (PD). At the American Academy of Neurology (AAN) 2024 annual meeting, Roche presented positive four-year results from a six-year open-label extension of their Phase II “PASADENA” trial evaluating the efficacy of PRX-002 (prasinezumab), a potentially PD modifying monoclonal antibody. These latest results strengthen the […]
Read more

ACC 24: Novo Nordisk’s Semaglutide will continue to retain leading position in cardiovascular market, says GlobalData

At the American College of Cardiology’s 73rd Annual Scientific Session, a study from the Gardy Health system in Atlanta, Georgia, US was presented investigating the rates of heart failure hospitalizations (HFH) in heart failure with preserved ejection fraction (HFpEF) patients and diabetes patients on semaglutide. Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) developed by […]
Read more
1 … 79 80 81 82 83 … 136